Maravai LifeSciences Holdings Inc
MRVI2.215USD
-0.005-0.23%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
318.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Maravai LifeSciences Holdings Inc Unternehmen
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Unternehmensinformationen
BörsenkürzelMRVI
Name des UnternehmensMaravai LifeSciences Holdings Inc
IPO-datumNov 20, 2020
CEOMr. Bernd Brust
Anzahl der mitarbeiter570
WertpapierartOrdinary Share
GeschäftsjahresendeNov 20
Addresse10770 Wateridge Circle Suite 200
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18585460004
Websitehttps://www.maravai.com/
BörsenkürzelMRVI
IPO-datumNov 20, 2020
CEOMr. Bernd Brust
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Rebecca Buzzeo
Ms. Rebecca Buzzeo
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
224.73K
-28.71%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
199.91K
+80.47%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Dr. Murali K. Prahalad, Ph.D.
Dr. Murali K. Prahalad, Ph.D.
Independent Director
Independent Director
154.61K
+136.16%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Rebecca Buzzeo
Ms. Rebecca Buzzeo
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
224.73K
-28.71%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
North America
29.27M
62.47%
Asia Pacific
10.56M
22.53%
Europe, the Middle East and Africa
6.88M
14.68%
Latin and Central America
146.00K
0.31%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jun 14
Aktualisiert: Sat, Jun 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
GTCR Golder Rauner, LLC
14.00%
12 West Capital Management, L.P.
8.70%
The Vanguard Group, Inc.
6.52%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.80%
Other
59.18%
Aktionäre
Aktionäre
Anteil
GTCR Golder Rauner, LLC
14.00%
12 West Capital Management, L.P.
8.70%
The Vanguard Group, Inc.
6.52%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.80%
Other
59.18%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
29.22%
Investment Advisor
24.05%
Investment Advisor/Hedge Fund
16.48%
Private Equity
14.00%
Individual Investor
6.22%
Corporation
4.77%
Research Firm
4.09%
Pension Fund
0.34%
Bank and Trust
0.32%
Other
0.51%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
558
143.67M
99.79%
-29.37M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
2023Q1
633
130.54M
99.07%
-18.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
GTCR Golder Rauner, LLC
20.15M
14%
--
--
Mar 31, 2025
12 West Capital Management, L.P.
12.52M
8.7%
+930.00K
+8.02%
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
8.08%
-162.48K
-1.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.36M
5.81%
-121.20K
-1.43%
Mar 31, 2025
Braidwell LP
8.35M
5.8%
--
--
Mar 31, 2025
Hudson View Capital LLC
6.87M
4.77%
+6.87M
--
May 21, 2025
Mackenzie Investments
6.11M
4.25%
-69.09K
-1.12%
Mar 31, 2025
Renaissance Technologies LLC
4.11M
2.86%
+138.50K
+3.49%
Mar 31, 2025
Mirabella Financial Services LLP
3.74M
2.6%
+3.74M
--
Mar 31, 2025
Two Sigma Investments, LP
3.67M
2.55%
+3.35M
+1026.80%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Royce Quant Small-Cap Quality Value ETF
0.38%
Global X Genomics & Biotechnology ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Mehr Anzeigen
Royce Quant Small-Cap Quality Value ETF
Anteil0.38%
Global X Genomics & Biotechnology ETF
Anteil0.36%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.12%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.01%
Schwab U.S. Small-Cap ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
